Patents
Literature
4 results about "Nucleic acid analogue" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Nucleic acid analogues are compounds which are analogous (structurally similar) to naturally occurring RNA and DNA, used in medicine and in molecular biology research. Nucleic acids are chains of nucleotides, which are composed of three parts: a phosphate backbone, a pentose sugar, either ribose or deoxyribose, and one of four nucleobases. An analogue may have any of these altered. Typically the analogue nucleobases confer, among other things, different base pairing and base stacking properties. Examples include universal bases, which can pair with all four canonical bases, and phosphate-sugar backbone analogues such as PNA, which affect the properties of the chain (PNA can even form a triple helix). Nucleic acid analogues are also called Xeno Nucleic Acid and represent one of the main pillars of xenobiology, the design of new-to-nature forms of life based on alternative biochemistries.
Use of structures for nucleic acid delivery in hematopoietic system tumor treatment
The present invention is a nucleic acid delivery structure for use in the treatment of hematopoietic tumors, characterized by having an association structure in which a nucleic acid analogue represented by formula (1) and a nucleic acid to be delivered comprising microRNA that regulates an oncogene KRAS network are associated by electrostatic interaction. L-(S2) s-H-(S1) t-N (1) (wherein N represents a cationic artificial nucleic acid, H represents a hydrophilic polymer, S1 represents a spacer 1, S2 represents a spacer 2, and L represents a ligand; n has a constituent unit in which a base is bonded to a hexose selected from ribose and deoxyribose, a linking structure for linking the two constituent units, and a skeleton structure comprising a cationic group; the cationic artificial nucleic acid can be associated by electrostatic interaction between the phosphate group of the nucleic acid to be delivered and the cationic group. ).
Owner:THE JAPAN SCI & TECH AGENCY
Nucleic acid detection composition based on differently modified templates, kit, and method
PCT designated stageWO2026130213A1Microbiological testing/measurementDNA/RNA fragmentationNucleic acid detectionNucleic acid analogue
Provided are a capture oligonucleotide, composition or kit for nucleic acid amplification, and a method. Specifically, the capture oligonucleotide comprises, from the 5' end to the 3' end, a universal sequence (3s) and a binding capture sequence (1s); wherein (1), the binding capture sequence (1s) is at least partially identical to the 5' end sequence of a target molecule or the binding capture sequence (1s) is at least partially identical to the 3' end sequence of a specific modification site on the target molecule; (2), the capture oligonucleotide further comprises a nucleic acid extension-blocking modification located at the 3' end of the binding capture sequence (1s); and optionally (3), the 3' end of the binding capture sequence (1s) has a nucleic acid analogue modification. Also provided are a composition or kit used for nucleic acid amplification detection, a detection system, and a method. The product and method can achieve nucleic acid detection with good specificity and high sensitivity.
Owner:SHANGHAI SCI-TECH INNO CENTER FOR INFECTION & IMMUNITY
Nucleic acids and nucleic acid analogs for treating, preventing, and disrupting pathological polynucleotide-binding protein inclusions
Disclosed herein are methods to treat a neurodegenerative disease comprising administering to a subject with a neurodegenerative disease a therapeutically effective amount of a polynucleotide that binds a nucleic acid-binding polypeptide, wherein the nucleic acid-binding polypeptide can aggregate in cells and is associated with a neurodegenerative disease. Also disclosed are methods to inhibit protein aggregation in a cell comprising contacting the cell with a composition comprising a polynucleotide that binds a nucleic acid-binding polypeptide, wherein the nucleic acid-binding polypeptide can aggregate in cells and is associated with a neurodegenerative disease. Additionally disclosed are compositions comprising a polynucleotide that binds a nucleic acid-binding polypeptide, wherein the nucleic acid-binding polypeptide can aggregate in cells and is associated with a neurodegenerative disease.
Owner:UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION +1
Structure for nucleic acid delivery, method for producing structure for nucleic acid delivery, and medicine
PCT designated stageWO2025225509A1Organic active ingredientsMacromolecular non-active ingredientsMorpholineCarboxylic acid
The present disclosure relates to a structure for nucleic acid delivery, said structure being characterized by having an association structure in which a nucleic acid analog represented by formula (1) and a nucleic acid to be delivered are associated by electrostatic interaction. (In the formula: N represents a cationic artificial nucleic acid including constituent units in which a base is bonded to a ring structure selected from ribose, deoxyribose, and morpholine, and a linking structure that has a cationic group and links two constituent units; H represents a hydrophilic polymer; S1 represents a spacer 1; S2 represents a spacer 2; L represents a ligand selected from C5 or lower saccharides and derivatives thereof, alcohols, and carboxylic acids; s represents 0 or 1; t represents 0 or 1; and the cationic artificial nucleic acid may be associated by electrostatic interaction between the cationic group and a phosphate group of the nucleic acid to be delivered).
Owner:THE JAPAN SCI & TECH AGENCY